RATIONALE: The meta-Analysis of Cell-based CaRdiac study is the first prospectively declared collaborative multinational database, including individual data of patients with ischemic heart disease treated with cell therapy. OBJECTIVE: We analyzed the safety and efficacy of intracoronary cell therapy after acute myocardial infarction (AMI), including individual patient data from 12 randomized trials (ASTAMI, Aalst, BOOST, BONAMI, CADUCEUS, FINCELL, REGENT, REPAIR-AMI, SCAMI, SWISS-AMI, TIME, LATE-TIME; n=1252). METHODS AND RESULTS: The primary end point was freedom from combined major adverse cardiac and cerebrovascular events (including all-cause death, AMI recurrance, stroke, and target vessel revascularization). The secondary end point was freedom from hard clinical end points (death, AMI recurrence, or stroke), assessed with random-effects meta-analyses and Cox regressions for interactions. Secondary efficacy end points included changes in end-diastolic volume, end-systolic volume, and ejection fraction, analyzed with random-effects meta-analyses and ANCOVA. We reported weighted mean differences between cell therapy and control groups. No effect of cell therapy on major adverse cardiac and cerebrovascular events (14.0% versus 16.3%; hazard ratio, 0.86; 95% confidence interval, 0.63-1.18) or death (1.4% versus 2.1%) or death/AMI recurrence/stroke (2.9% versus 4.7%) was identified in comparison with controls. No changes in ejection fraction (mean difference: 0.96%; 95% confidence interval, -0.2 to 2.1), end-diastolic volume, or systolic volume were observed compared with controls. These results were not influenced by anterior AMI location, reduced baseline ejection fraction, or the use of MRI for assessing left ventricular parameters. CONCLUSIONS: This meta-analysis of individual patient data from randomized trials in patients with recent AMI revealed that intracoronary cell therapy provided no benefit, in terms of clinical events or changes in left ventricular function. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT01098591.
RATIONALE: The meta-Analysis of Cell-based CaRdiac study is the first prospectively declared collaborative multinational database, including individual data of patients with ischemic heart disease treated with cell therapy. OBJECTIVE: We analyzed the safety and efficacy of intracoronary cell therapy after acute myocardial infarction (AMI), including individual patient data from 12 randomized trials (ASTAMI, Aalst, BOOST, BONAMI, CADUCEUS, FINCELL, REGENT, REPAIR-AMI, SCAMI, SWISS-AMI, TIME, LATE-TIME; n=1252). METHODS AND RESULTS: The primary end point was freedom from combined major adverse cardiac and cerebrovascular events (including all-cause death, AMI recurrance, stroke, and target vessel revascularization). The secondary end point was freedom from hard clinical end points (death, AMI recurrence, or stroke), assessed with random-effects meta-analyses and Cox regressions for interactions. Secondary efficacy end points included changes in end-diastolic volume, end-systolic volume, and ejection fraction, analyzed with random-effects meta-analyses and ANCOVA. We reported weighted mean differences between cell therapy and control groups. No effect of cell therapy on major adverse cardiac and cerebrovascular events (14.0% versus 16.3%; hazard ratio, 0.86; 95% confidence interval, 0.63-1.18) or death (1.4% versus 2.1%) or death/AMI recurrence/stroke (2.9% versus 4.7%) was identified in comparison with controls. No changes in ejection fraction (mean difference: 0.96%; 95% confidence interval, -0.2 to 2.1), end-diastolic volume, or systolic volume were observed compared with controls. These results were not influenced by anterior AMI location, reduced baseline ejection fraction, or the use of MRI for assessing left ventricular parameters. CONCLUSIONS: This meta-analysis of individual patient data from randomized trials in patients with recent AMI revealed that intracoronary cell therapy provided no benefit, in terms of clinical events or changes in left ventricular function. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT01098591.
Authors: Kai C Wollert; Gerd P Meyer; Joachim Lotz; Stefanie Ringes-Lichtenberg; Peter Lippolt; Christiane Breidenbach; Stephanie Fichtner; Thomas Korte; Burkhard Hornig; Diethelm Messinger; Lubomir Arseniev; Bernd Hertenstein; Arnold Ganser; Helmut Drexler Journal: Lancet Date: 2004 Jul 10-16 Impact factor: 79.321
Authors: Robert D Simari; Lemuel A Moyé; Sonia I Skarlatos; Stephen G Ellis; David X M Zhao; James T Willerson; Timothy D Henry; Carl J Pepine Journal: J Cardiovasc Transl Res Date: 2010-02 Impact factor: 4.132
Authors: Volker Schächinger; Sandra Erbs; Albrecht Elsässer; Werner Haberbosch; Rainer Hambrecht; Hans Hölschermann; Jiangtao Yu; Roberto Corti; Detlef G Mathey; Christian W Hamm; Tim Süselbeck; Birgit Assmus; Torsten Tonn; Stefanie Dimmeler; Andreas M Zeiher Journal: N Engl J Med Date: 2006-09-21 Impact factor: 91.245
Authors: D F Stroup; J A Berlin; S C Morton; I Olkin; G D Williamson; D Rennie; D Moher; B J Becker; T A Sipe; S B Thacker Journal: JAMA Date: 2000-04-19 Impact factor: 56.272
Authors: Michał Tendera; Wojciech Wojakowski; Witold Ruzyłło; Lidia Chojnowska; Cezary Kepka; Wiesława Tracz; Piotr Musiałek; Wiesława Piwowarska; Jadwiga Nessler; Paweł Buszman; Stefan Grajek; Piotr Breborowicz; Marcin Majka; Mariusz Z Ratajczak Journal: Eur Heart J Date: 2009-02-10 Impact factor: 29.983
Authors: Ahmed Abdel-Latif; Roberto Bolli; Imad M Tleyjeh; Victor M Montori; Emerson C Perin; Carlton A Hornung; Ewa K Zuba-Surma; Mouaz Al-Mallah; Buddhadeb Dawn Journal: Arch Intern Med Date: 2007-05-28
Authors: Johanna A Miettinen; Kari Ylitalo; Pirjo Hedberg; Jari Jokelainen; Kari Kervinen; Matti Niemelä; Marjaana Säily; Pirjo Koistinen; Eeva-Riitta Savolainen; Heikki Ukkonen; Mikko Pietilä; K E Juhani Airaksinen; Juhani Knuuti; Olli Vuolteenaho; Timo H Mäkikallio; Heikki V Huikuri Journal: Heart Date: 2009-11-11 Impact factor: 5.994
Authors: Elena Cambria; Julia Steiger; Julia Günter; Annina Bopp; Petra Wolint; Simon P Hoerstrup; Maximilian Y Emmert Journal: Transfus Med Hemother Date: 2016-07-26 Impact factor: 3.747
Authors: Arshed A Quyyumi; Alejandro Vasquez; Dean J Kereiakes; Marc Klapholz; Gary L Schaer; Ahmed Abdel-Latif; Stephen Frohwein; Timothy D Henry; Richard A Schatz; Nabil Dib; Catalin Toma; Charles J Davidson; Gregory W Barsness; David M Shavelle; Martin Cohen; Joseph Poole; Thomas Moss; Pamela Hyde; Anna Maria Kanakaraj; Vitaly Druker; Amy Chung; Candice Junge; Robert A Preti; Robin L Smith; David J Mazzo; Andrew Pecora; Douglas W Losordo Journal: Circ Res Date: 2016-11-07 Impact factor: 17.367